MAb17-1A, a low affinity monoclonal antibody against EpCAM, is successfully used in Germany for breast and colon carcinoma therapy [12, 13] and CD3/17-1A, a bispecific scFv, is demonstrated to have cytotoxicity to EpCAM-positive tumor cells in vitro [14]. This evidence concerns the gene EPCAM and colon carcinoma.